SCHEMBL3149168

SCHEMBL3149168

COc1cc(Cl)ccc1ON(c1ccccc1)S(=O)(=O)c1ccc(C(=O)NCCCN2CCCCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
DRD2 P14416 5/20 0.50
DRD3 P35462 5/20 0.50
DRD4 P21917 3/20 0.50
CCR2 P41597 3/20 0.48
KCNH2 Q12809 1/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2D6 P10635 1/20 0.47
MEN1 O00255 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3157190 0.95 CCR2 (0.52) F10SMN1; SMN2ALDH1A1TDP1DRD2
SCHEMBL3148182 0.91 F10 (0.51) F10SMN1; SMN2ALDH1A1TDP1DRD2
SCHEMBL3145273 0.88 ALDH1A1 (0.49) F10SMN1; SMN2ALDH1A1TDP1DRD2
SCHEMBL3044072 0.87 F10 (0.46) F10SMN1; SMN2ALDH1A1TDP1CCR2
SCHEMBL3153773 0.85 ALDH1A1 (0.45) F10SMN1; SMN2ALDH1A1TDP1DRD2
SCHEMBL3140709 0.85 NAMPT (0.47) F10SMN1; SMN2ALDH1A1TDP1DRD2
SCHEMBL3054196 0.85 CCR2 (0.45) F10SMN1; SMN2ALDH1A1DRD2DRD3
SCHEMBL3153267 0.84 DRD2 (0.46) SMN1; SMN2ALDH1A1TDP1DRD2DRD3
SCHEMBL3148946 0.84 BDKRB1 (0.44) SMN1; SMN2ALDH1A1DRD2DRD3CCR2
SCHEMBL3148189 0.83 POLB (0.52) F10DRD4CCR2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 F10 597/4885SMN1; SMN2 3719/4885ALDH1A1 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.